TY - JOUR
T1 - Thalamic DBS with a constant-current device in essential tremor
T2 - A controlled clinical trial
AU - for the SJM DBS ET Study Group
AU - Wharen, Robert E.
AU - Okun, Michael S.
AU - Guthrie, Barton L.
AU - Uitti, Ryan J.
AU - Larson, Paul
AU - Foote, Kelly
AU - Walker, Harrison
AU - Marshall, Frederick J.
AU - Schwalb, Jason
AU - Ford, Blair
AU - Jankovic, Joseph
AU - Simpson, Richard
AU - Dashtipour, Khashayar
AU - Phibbs, Fenna
AU - Neimat, Joseph S.
AU - Stewart, R. Malcolm
AU - Peichel, De Lea
AU - Pahwa, Rajesh
AU - Ostrem, Jill L.
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/7
Y1 - 2017/7
N2 - Introduction This study of thalamic deep brain stimulation (DBS) investigated whether a novel constant-current device improves tremor and activities of daily living (ADL) in patients with essential tremor (ET). Methods A prospective, controlled, multicenter study was conducted at 12 academic centers. We investigated the safety and efficacy of unilateral and bilateral constant-current DBS of the ventralis intermedius (VIM) nucleus of the thalamus in patients with essential tremor whose tremor was inadequately controlled by medications. The primary outcome measure was a rater-blinded assessment of the change in the target limb tremor score in the stimulation-on versus stimulation-off state six months following surgery. Multiple secondary outcomes were assessed at one-year follow-up, including motor, mood, and quality-of-life measures. Results 127 patients were implanted with VIM DBS. The blinded, primary outcome variable (n = 76) revealed a mean improvement of 1.25 ± 1.26 points in the target limb tremor rating scale (TRS) score in the arm contralateral to DBS (p < 0.001). Secondary outcome variables at one year revealed significant improvements (p ≤ 0.001) in quality of life, depression symptoms, and ADL scores. Forty-seven patients had a second contralateral VIM-DBS, and this group demonstrated reduction in second-sided tremor at 180 days (p < 0.001). Serious adverse events related to the surgery included infection (n = 3), intracranial hemorrhage (n = 3), and device explantation (n = 3). Conclusion Unilateral and bilateral constant-current VIM DBS significantly improves upper extremity tremor, ADL, quality of life, and depression in patients with severe ET.
AB - Introduction This study of thalamic deep brain stimulation (DBS) investigated whether a novel constant-current device improves tremor and activities of daily living (ADL) in patients with essential tremor (ET). Methods A prospective, controlled, multicenter study was conducted at 12 academic centers. We investigated the safety and efficacy of unilateral and bilateral constant-current DBS of the ventralis intermedius (VIM) nucleus of the thalamus in patients with essential tremor whose tremor was inadequately controlled by medications. The primary outcome measure was a rater-blinded assessment of the change in the target limb tremor score in the stimulation-on versus stimulation-off state six months following surgery. Multiple secondary outcomes were assessed at one-year follow-up, including motor, mood, and quality-of-life measures. Results 127 patients were implanted with VIM DBS. The blinded, primary outcome variable (n = 76) revealed a mean improvement of 1.25 ± 1.26 points in the target limb tremor rating scale (TRS) score in the arm contralateral to DBS (p < 0.001). Secondary outcome variables at one year revealed significant improvements (p ≤ 0.001) in quality of life, depression symptoms, and ADL scores. Forty-seven patients had a second contralateral VIM-DBS, and this group demonstrated reduction in second-sided tremor at 180 days (p < 0.001). Serious adverse events related to the surgery included infection (n = 3), intracranial hemorrhage (n = 3), and device explantation (n = 3). Conclusion Unilateral and bilateral constant-current VIM DBS significantly improves upper extremity tremor, ADL, quality of life, and depression in patients with severe ET.
KW - Deep brain stimulation
KW - Essential tremor
KW - Thalamus
KW - Ventralis intermedius nucleus
UR - http://www.scopus.com/inward/record.url?scp=85017230327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017230327&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2017.03.017
DO - 10.1016/j.parkreldis.2017.03.017
M3 - Article
C2 - 28400200
SN - 1353-8020
VL - 40
SP - 18
EP - 26
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -